Navigation Links
Actemra Post-Launch Success Continues to Gain Momentum with Broader Adoption Compared to Biologic Analog Launches and a Professional Marketing Campaign That Resonates with Rheumatologists
Date:8/31/2010

EXTON, Pa., Aug. 31 /PRNewswire/ -- BioTrends has released the third and final wave of LaunchTrends®: ACTEMRA. Actemra (tocilizumab), marketed by Roche-Genentech, is the first humanized IL-6 receptor inhibitor agent approved for moderate-to-severe rheumatoid arthritis (RA) patients with an inadequate response to one or more TNF-alpha inhibitors. This report is derived from on-line survey responses from 75 rheumatologists and qualitative interviews with a subset of the survey respondents.

Rheumatologists report using Actemra with clinical success in patients who failed one or more TNF-alpha inhibitors despite the need for more frequent blood monitoring of liver function, lipid profile, and neutrophil and platelet counts. Each of these side effect issues has had varying degrees of impact on physicians' treatment patterns.

The breadth and depth of adoption of Actemra is greater than that of other biologic analogs in RA at a six-month post-launch timeframe. Patient origination is largely derived from the three established TNF-alpha inhibitors (Amgen/Pfizer's Enbrel, Abbott's Humira and Centocor Ortho Biotech's Remicade), although rheumatologists consider Actemra to compete more directly with (i.e., displace) Remicade and Bristol-Myers Squibb's Orencia.  

The core efficacy messages of Actemra's professional marketing campaign resonate strongly with rheumatologists. Based on a quantitative derived importance analysis supported by qualitative interviews with physicians, these core messages have a direct influence on physicians' perceptions of biologic performance in their clinical practice. In some instances, these efficacy attributes are competitive advantages for Actemra over other biologic agents.  

This study represents the final wave of LaunchTrends: Actemra. Trends are compared over time including trial and usage of Actemra, patient types, line of therapy, product perceptions, promotional detai
'/>"/>

SOURCE BioTrends Research Group, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. New Report by BioTrends Research Group To Highlight The Launch Of ACTEMRA (tocilizumab)
2. Ninety Eight Percent of Surveyed Rheumatologists Will Prescribe Roches Actemra for Rheumatoid Arthritis
3. Data Demonstrated ACTEMRA(R) (tocilizumab) Significantly Inhibited Progression of Structural Joint Damage in Rheumatoid Arthritis Patients
4. Two-Year Data Reinforce Effect of ACTEMRA(R) (tocilizumab) in Inhibiting Progression of Joint Damage and Improving Physical Function in Rheumatoid Arthritis Patients
5. Roche and FDA Agree on Pathway Towards U.S. Approval of ACTEMRA(R) (tocilizumab)
6. New Study Demonstrated ACTEMRA(R) (tocilizumab) Inhibited Progression of Joint Damage in Rheumatoid Arthritis Patients
7. ACTEMRA (R) (tocilizumab) Significantly Reduced Signs and Symptoms of Rheumatoid Arthritis in Patients Who Failed Prior Treatments
8. ACTEMRA(R) (tocilizumab) Significantly Reduces Rheumatoid Arthritis Signs and Symptoms Regardless of Previous Therapy in Two New Global Studies
9. New Study Demonstrates ACTEMRA(R) (tocilizumab) Inhibits Progression of Joint Damage in Rheumatoid Arthritis Patients
10. International ACTEMRA Rheumatoid Arthritis Study Highlighted in The Lancet
11. Roche Submits Application for FDA Approval of ACTEMRA(R) for the Treatment of Rheumatoid Arthritis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/1/2014)... 2014   Plexus Information Systems, Inc. ... Management Systems (AIMS), announced a partnership with ... owned subsidiary of Quality Systems, Inc. and a ... solutions.  Logo - http://photos.prnewswire.com/prnh/20140930/149406 ... This partnership extends the NextGen Healthcare product ...
(Date:10/1/2014)... Oct. 1, 2014 NeuroCall, Inc., ("NeuroCall") announced ... its Telestroke and Teleneurology services. Dr. Ricardo Garcia-Rivera ... "We are extremely proud that our quality of service ... continue to provide lifesaving support and continuity of care ... throughout the United States ." ...
(Date:10/1/2014)... Oct. 1, 2014 Quantum Materials Corp ... production of photoactive quantum dots for use in ... offering numerous advantages for solar power generation, the ... of quantum dots with which to develop thin ... from commercial utilization and acceptance. The company is ...
Breaking Medicine Technology:Plexus IS' Anesthesia Documentation Solution Strengthens NextGen Healthcare Product Offering 2Plexus IS' Anesthesia Documentation Solution Strengthens NextGen Healthcare Product Offering 3NeuroCall Awarded Joint Commission Accreditation 2Quantum Materials Scaling Up Photoactive Quantum Dot Production for Solar Power Generation 2Quantum Materials Scaling Up Photoactive Quantum Dot Production for Solar Power Generation 3
... 16, 2007 - ZIOPHARM Oncology,Inc. (NASDAQ: ZIOP) announced ... active form of ZIO-201 (isophosphoramide mustard,- IPM) at ... in Los Angeles. Data presented demonstrated oral availability,of ... models, including,those with ifosfamide (IFOS) and cyclophosphamide resistant ...
... 2007 - Somanta,Pharmaceuticals (OTCBB:SMPM) today announced that ... later today at the American,Association for Cancer ... poster presentation is entitled "Cytotoxicity of novel,alkylating ... and DNA Mismatch Repair defects," and focuses ...
Cached Medicine Technology:ZIOPHARM Presents Data on Orally Active ZIO-201 at AACR 2ZIOPHARM Presents Data on Orally Active ZIO-201 at AACR 3Somanta Announces the Presentation of Alchemix Data at The American,Association for Cancer Research Annual Meeting 2
(Date:10/1/2014)... 2014 First Warning Systems, a pioneer ... changes throughout the body, announced the company is changing ... the company’s breadth of upcoming product releases. The initial ... technology. , “Our initial focus will be an ‘Internet ... abnormal circadian cellular changes over time,” said Rob Royea, ...
(Date:10/1/2014)... Join the more than 80 golfers who ... first ever charity golf tournament to benefit Project HEAL, a ... who cannot afford treatment. The tournament will be held Monday, ... , The day-long event starts with 10:30 a.m. check-in ... dinner will begin at 5 p.m. and will include an ...
(Date:10/1/2014)... Innovations announces the upcoming airing of Innovations with ... 20, 2014 at 7:30 a.m. EST/PT via Discovery Channel. ... scenes to learn about Break the Cycle’s comprehensive dating ... help and information Break the Cycle provides to teens ... abuse, how to navigate the legal system, and provides ...
(Date:10/1/2014)... NC (PRWEB) October 01, 2014 Scientists ... of three drugs that target immune system proteins has ... Mesothelioma has just posted details of the new study ... story now. , Researchers in the UWA School ... and anti-CTLA-4 drugs to mice with mesothelioma with promising ...
(Date:10/1/2014)... 01, 2014 October is national Breast ... early detection plans while raising money for breast cancer ... Cancer Awareness Month in the effort to find ... promote the importance of having access to clean, healthy ... be linked to certain forms of cancer. , ...
Breaking Medicine News(10 mins):Health News:First Warning Systems Changes Name to Cyrcadia Health to Better Reflect Core Competency and Goals of Company 2Health News:First Warning Systems Changes Name to Cyrcadia Health to Better Reflect Core Competency and Goals of Company 3Health News:First Warning Systems Changes Name to Cyrcadia Health to Better Reflect Core Competency and Goals of Company 4Health News:Project HEAL Benefit Golf Tournament Gaining Momentum 2Health News:Project HEAL Benefit Golf Tournament Gaining Momentum 3Health News:Innovations to Explore Breakthroughs in Health and Wellness in Upcoming Episode Airing Monday, October 20, 2014 via Discovery Channel 2Health News:New Mesothelioma Study Says Mice Cured by Immuntherapy “Cocktail”, Reports Surviving Mesothelioma 2Health News:Pelican Water Supports Breast Cancer Awareness Month with Order Donations 2
... not exactly help in memory recall. The need of the hour ... 30 seconds. You might look weird doing this in an ... the forgotten facts and figures. ,A study shows that ... eye from one end to the other for 30 seconds every ...
... tenth of Idahos trout population and a loss of ... The outbreak of Ichthyophthirius multifilis has killed around 250,000 trout ... Fish and Game hatchery, in Nampa. This is the second ... probably resulted when stress from overcrowding weakened the fish, making ...
... regard to doctor-patient ratio in various State Government Hospitals ... from case to case depending upon various factors like ... patient-care required i.e. indoor/outdoor. According to the Medical Council ... out to 1:1722. ,The patient nurse ...
... country are 73557. There are 22273 numbers of doctors at ... as on March 2006. As on 1.1.2007, total numbers of ... 340308 beds are available in urban government hospitals including Community ... 92.4% of CHCs are located in government buildings. As on ...
... Lara has thrown a punch at the West Indies Cricket ... named after him. ,He commended the persons and ... Lara Cancer Center for their "teamwork, integrity and use of ... Cricket Board. ,His statement underlines the fact there ...
... quality at western Yamuna canal meets the desired water ... Haridwar, is carrying out water quality monitoring and analysis ... Yamunanagar upstream, Yamunanagar downstream, Panipat downstream and Sonepat upstream ... The monitoring results are being submitted by PCRI to ...
Cached Medicine News:Health News:Eyeing a Good Memory - Not an Exercise in Futility! 2Health News:Disease Outbreak Claims Trout From Idaho Hatchery 2
Hudson Cranial Drill, complete, consisting of: brace; with extension piece and 4 burs...
23 cm - 9, adult size, for skull thickness up to 12 mm....
Length-9 (229 mm) Tapered retractor blades....
Pattie Tray...
Medicine Products: